1. In Vivo
  2. >>Market Intelligence

Harbingers For IPF Drug Development

 
• By Mark Ratner

Roche’s decision to discontinue a Phase III program in idiopathic pulmonary fibrosis was the latest of several recent late-stage clinical failures, emblematic of the difficulty in finding new approaches to treat the disease.

lung illustration

The near- and intermediate-term landscape for idiopathic pulmonary fibrosis (IPF) drug development shifted when, as part of its FY22 financial update in February,Roche Holding AGdisclosed that it was discontinuing development of the Phase III candidate PRM-151 (recombinant human pentraxin-2), the lead compound it acquired when it bought Promedior Inc. in 2019. [See Deal]

“With one less Phase III program recruiting patients and one less potential competitor in the treatment landscape, we see potential...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Intelligence

More from In Vivo

Deals In Depth: June 2025

 
• By Deanna Kamienski and Maureen Riordan

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By Jo Shorthouse

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.